Certara, Inc. (CERT) Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.
Sector: Services-Prepackaged Software
Industry: Medical - Healthcare Information Services
Certara, Inc. NASDAQ:CERT Healthcare · Medical - Healthcare Information Services
Pre Pre-market $12.00 Close $12.05 0.00% AH $12.05 Now $12.00 PM VOL 2K $ Vol ≈ $26K RVOL 0.67x
Close $12.05 -1.07% AH $12.05 -0.41% since
Mkt Cap $1.84B
PM VOL 2K sh
$ Vol ≈$26K
RVOL 0.67×
Press Release ⚠ 4
Certara Reports Third Quarter 2026 Financial Results
Certara reported Q3 2026 revenue of $94.9 million, up 4% year-over-year, with software revenue up 11% to $48.8 million — its first double-digit software quarter in two years.
Services revenue declined 2% to $46.1 million and services bookings fell 5%, while total bookings rose 4% to $92.5 million. Adjusted EBITDA grew 6% to $30.2 million with margin expanding to 31.8%, up more than 370 basis points from Q2.
The company narrowed its FY26 revenue growth guidance to 2-3% and set adjusted diluted EPS at $0.31-$0.34. It also appointed Grant Peterson, previously CTO at DocuSign, as Chief Product Officer.
• 4d ago AI analysis › Press Release ● Major
Birchtech Files Brief in Federal Circuit Supporting the $78 Million Patent Infringement Judgment Against CERT Defendants
globenewswire.com • 6d ago Press Release
Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026
Certara announced it will release third quarter 2026 financial results before market open on Thursday, November 5th, 2026.
Management will host a conference call at 8:30AM ET the same day, with a live webcast and replay available on the company's investor relations site.
This is a scheduling notice only; no results or guidance are included.
• 14d ago AI analysis › Press Release ⚠ 3
Higher Grades, More Ounces, Longer Life: The Playbook Taking Shape in Argentina’s Gold Belt
This is a paid promotional commentary distributed by Canada News Group, sponsored by Cerrado Gold, surveying gold producers in Argentina's Santa Cruz province and beyond.
Aris Mining is mentioned in a recap: Q3 2026 production of 69.3 thousand ounces from Colombian operations, with year-to-date output of 217.3 thousand ounces, up 16%, tracking the lower end of 300,000-350,000 ounce guidance. Marmato's 5,000 tpd CIP plant remains on track for first gold in Q4 2026.
The release carries an explicit conflict-of-interest disclosure: the publisher was paid by Cerrado Gold and reserves the right to trade its shares. Treat the promotional content as low-signal marketing rather than issuer disclosure.
• 19d ago AI analysis › Press Release
The Small Cap Showcase Highlights 8 Public Companies at Their Investor Conference Today
The Small Cap Showcase is hosting an investor conference in New York City on October 1, 2026, featuring presentations from eight micro and small cap public companies, including ACCESS Newswire (NYSE: ACCS) presenting at 3:00 PM ET.
ACCES's presentation, along with the other company webcasts, is available to registered attendees via the conference website and provided links.
The event includes one-on-one meetings with qualified investors and a lunch talk on the IPO market, but contains no new company-specific financial or operational disclosure.
• 1mo ago AI analysis › Press Release ⚠ 2
Presenting on Emerging Growth Conference 96 Day 2 on September 24. Register to live stream.
Bimergen Energy Corporation (NYSE American: BESS) is scheduled to present at the 96th Emerging Growth Conference on September 23, 2026, from 3:55 to 4:05 PM Eastern, with Co-CEO & CFO Bob Brilon speaking.
This is a conference-schedule announcement issued by EmergingGrowth.com, not a company disclosure; no financial results, guidance, or business developments are included.
Note that presenting companies may pay fees in cash and securities to the organizer, so this is promotional placement rather than news of substance.
• 1mo ago AI analysis › Press Release ⚠ 6
The Market Just Told You Which Layer Of AI Biology It Is Paying For
This is a paid investor-awareness article promoting MindWalk Holdings (HYFT), not a disclosure from Certara; Market Equities Limited discloses it was compensated to increase visibility for MindWalk.
Certara's Q2 results are cited only as a foil: revenue of $93.3 million up 1%, adjusted EPS of $0.08 versus $0.10 consensus, and a roughly 16% share decline — data investors may already know from Certara's own August 4 filing.
The article's argument — that markets reward proprietary data layers over software or AI-native models — is promotional commentary from an interested publisher and should be treated as marketing, not analysis.
• 2mo ago AI analysis › Press Release ⚠ 2
This Gold Miner's Margin Per Ounce Just Went From $914 to $2,401
This press release is a paid advertisement for Cerrado Gold Inc., referencing Barrick's operations in Argentina as a sector benchmark.
The text notes that Barrick has committed US$271 million through 2027 to extend the life of its Veladero mine to 2035, signaling confidence in the jurisdiction.
No new financial or operational updates are provided for Barrick in this release.
• 2mo ago AI analysis › Press Release ⚠ 3
Certara Reports Second Quarter 2026 Financial Results
Certara reported Q2 revenue of $93.3 million, up 1% year-over-year, but swung to a net loss of $6.1 million compared to net income of $1.5 million in the prior year.
Adjusted EBITDA decreased 3% to $26.2 million, while the company reaffirmed full-year revenue guidance of 0% to 4% growth on a continuing operations basis.
The board completed a $100 million share repurchase program and authorized an additional $50 million, signaling confidence amidst a restructuring that cut roughly 5% of the workforce.
Leadership was bolstered by the appointment of Julien Perrier as Chief Commercial Officer to oversee the newly aligned commercial model.
• 3mo ago AI analysis › Press Release
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026
Certara announced it will release its second quarter 2026 financial results before the market opens on Tuesday, August 4, 2026.
Management is scheduled to host a conference call at 8:30 AM ET to discuss the results, with investors required to register online in advance.
A live and archived webcast of the call will be available on the Investors section of the company website.
• 3mo ago AI analysis › Press Release
Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit
Certara has partnered with NVIDIA to integrate the BioNeMo Agent Toolkit into its open integrated AI platform for drug development.
The collaboration aims to unify Certara’s scientific software, regulatory expertise, and proprietary datasets with NVIDIA’s AI-first agentic frameworks to accelerate insight generation.
Specialized AI agents will reason over Certara’s models and data to optimize dosing strategies, simulate clinical scenarios, and assemble regulatory-ready evidence while keeping scientists in the loop.
• 4mo ago AI analysis › Press Release
Q2 Investor Summit Virtual Live Wednesday June 24
bioAffinity Technologies is scheduled to present at the Q2 Investor Summit virtual event on Wednesday, June 24, 2026.
The company is set to present at 10:00 AM ET, where management will discuss business strategies and recent developments.
The event allows for live Q&A sessions and scheduled one-on-one meetings with management teams.
• 4mo ago AI analysis › Press Release ⚠ 1
Certara Announces CFO Transition
Certara announced that CFO John Gallagher will resign effective July 14, 2026, concluding his tenure as the company's finance chief.
Faiz Mohammed, Senior Vice President of Finance and Treasurer, will serve as Interim CFO while the company conducts a search for a permanent successor.
Concurrent with the announcement, Certara reaffirmed its 2026 financial guidance that was previously provided on May 11, 2026.
• 4mo ago AI analysis › Press Release ⚠ 1
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
Equity Insider published a paid commentary on behalf of MindWalk Holdings Corp., arguing that the value in AI drug discovery lies in the underlying biological data layer rather than just the models.
The article profiles MindWalk's 'context layer' strategy and mentions Absci (ABSI) as a peer focused on generative design and a participant in a recent industry panel.
This third-party piece references MindWalk's financial results and platform launches to support its investment thesis regarding the sector.
• 4mo ago AI analysis › Press Release
Certara to Participate in Upcoming Investor Conferences
Certara announced that management will participate in three upcoming investor conferences in May and June.
The schedule includes appearances at the RBC CM Global Healthcare Conference on May 19, William Blair’s 46th Annual Growth Stock Conference on June 2, and the Jefferies Global Healthcare Conference on June 3.
Live webcasts of the RBC and Jefferies sessions will be available on the company’s investor relations website.
• 5mo ago AI analysis › Press Release
Certara Reports First Quarter 2026 Financial Results
globenewswire.com • 5mo ago Press Release
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development
Certara has entered a strategic partnership with Altasciences to integrate its model-informed drug development services into Altasciences' Acceleration Platform.
The collaboration aims to enable sponsors to establish proof of mechanism earlier and design more efficient studies by embedding modeling insights directly into the execution of development programs.
Certara CEO Jon Resnick noted that this approach unlocks opportunities to improve early development decisions and accelerate the path to proof of concept for biotech innovators and investors.
• 6mo ago AI analysis › Press Release
Precious Metals & Critical Minerals Virtual Investor Conference Agenda Announced for May 5th – 7th
Atlas Critical Minerals Corporation is scheduled to present at the upcoming Precious Metals & Critical Minerals Virtual Investor Conference.
The company's presentation is slated for Thursday, May 7th, at 10:00 AM ET.
The event, hosted by Virtual Investor Conferences, allows investors to attend live sessions and schedule one-on-one meetings with management.
• 6mo ago AI analysis › Press Release ● Major
Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat
Certara agreed to sell its Regulatory and Medical Writing business to Veristat for total consideration of up to $135 million.
The divested unit generated $50 million in revenue and $17 million in adjusted EBITDA during 2025 and employs approximately 220 people.
Management intends to deploy the proceeds to accelerate investment in AI-integrated MIDD and Clinical Intelligence platforms, with updated 2026 guidance to follow upon the transaction's close in Q2.
• 6mo ago AI analysis › 
